| Literature DB >> 31319585 |
Cristina Cuerda1, Maria F Vasiloglou2, Loredana Arhip3.
Abstract
BACKGROUND: Anorexia Nervosa (AN) is a psychiatric disorder characterised by a physical and psychosocial deterioration due to an altered pattern on the intake and weight control. The severity of the disease is based on the degree of malnutrition. The objective of this article is to review the scientific evidence of the refeeding process of malnourished inpatients with AN; focusing on the clinical outcome.Entities:
Keywords: anorexia nervosa; length of stay; mortality; refeeding syndrome; weight gain
Year: 2019 PMID: 31319585 PMCID: PMC6679071 DOI: 10.3390/jcm8071042
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Diagnostic criteria of anorexia nervosa according to DSM-5 classification.
| Anorexia nervosa |
Restriction of energy intake relative to requirements leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. Significantly low weight is defined as a weight that is less than minimally normal or, for children and adolescents, less than that minimally expected. Intense fear of gaining weight or becoming fat, or persistent behaviour that interferes with weight gain, even though at a significantly low weight. Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight. |
Clinical manifestations of anorexia nervosa.
| Cardiovascular | Bradycardia and hypotension due to alterations in the autonomic nervous system. |
| Gastrointestinal | Delayed gastric emptying and constipation. |
| Neurological | Cortical atrophy and ventricular dilatation alterations. |
| Renal and Hydro electrolytic | Decrease in glomerular filtration rate. |
| Bone | Osteopenia. |
| Endocrinological | Hypogonadotropic hypogonadism. |
| Haematological | Bone marrow hypoplasia with gelatinous transformation presenting variable degrees of anaemia, leukopenia, and thrombocytopenia. |
| Dermatological | Russell’s sign. |
Criteria for hospitalisation in anorexia nervosa.
|
| |
| Adults | Bradycardia < 40 bpm or tachycardia > 110 bpm. |
| Children and adolescents | Bradycardia < 50 bpm. |
|
| |
| All ages | Suicidal ideation. |
Guidelines for the refeeding of malnourished anorexia nervosa patients.
| Guideline | Population | Kcal/kg |
|---|---|---|
| United Kingdom: National Institute for Health and Clinical Excellence (NICE), 2017 [ | Adults | 5–20 |
| United Kingdom: MARSIPAN: Management of Really Sick Patients with Anorexia Nervosa, 2014 [ | Adults | 5–20 |
| United Kingdom: Junior MARSIPAN: Management of Really Sick Patients under 18 with Anorexia Nervosa, 2012 [ | <18 years | 15–20 |
| American Psychiatric Association (APA), 2006 [ | Adults | 30–40 |
| American Dietetic Association (ADA), 2006 [ | Adults | 30–40 |
| Australia and New Zealand, 2004 [ | Adults | 15–20 (600–800 kcal/d) |
Example of a refeeding process in terms of macronutrient and micronutrient intake [19].
| Days | Recommendations |
|---|---|
| Day 1–3 |
Start with 10–15 kcal/kg (600–1000 kcal/day). Prophylactic electrolyte supplementation (P, K, Mg). Thiamine (200–300 mg/day). Vitamins (200% RDI). Minerals and trace elements (100% RDI). Restrict the contribution of fluids to a zero balance. Restrict sodium to <1 mmol/kg/day. Glucose and electrolyte levels and the appearance of oedema should be adequately monitored, since the highest risk of RS occurs in these early days. |
| Day 4–10 |
Calorie intake will increase to allow weight gain, continuing with electrolyte, vitamin and mineral supplementation and close monitoring. |
Figure 1Algorithm of the nutritional treatment in AN.
Studies in patients with anorexia nervosa reporting clinical outcomes of the nutritional treatment.
| Study | Study Type | Nº Patients | Mean Age (years) | Weight (kg) or BMI (kg/m2) at Admission | Weight (kg) or BMI (kg/m2) at Discharge | Length of Stay (days) | Kcal/kg or kcal/day at Admission | Type of Nutritional Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Rigaud et al., 2007 [ | RCT | a: 41 | a: 22.5 | a: 12.1 | a: 17.9 | 60 | a: 1000 (D0)–2450 (D14) | a: OD + TF | No RS |
| Diamanti et al., 2008 [ | Retrospective | a: 104 | 15 | a: 36.3 | a: 39.6 | a: 30.7 | 40 kcal/kg | a: OD + PN | No RS |
| Gentile et al., 2010 [ | Retrospective | 33 | 22.8 | 11.3 | 13.5 | 60 | 1408 | OD + TF + iv. glucose | No RS |
| Vignaud et al., 2010 [ | Retrospective | 68 | 31 | 12 | - | 7.6 (in ICU) | 22.3 kcal/kg | OD + TF + TPN | RS (10%) |
| Whitelaw et al., 2010 [ | Retrospective | 29 | 15.7 | 72.9% IBW | - | - | 1900–2200 (89% of patients) | OD + ONS + TF (7 patients) | Mild hypophosphataemia (37%) |
| Garber et al., 2012 [ | Prospective | 35 | 16.2 | 16.3 | - | 17 | 1205 | OD | No RS |
| Gentile et al., 2012 [ | Retrospective | 10 | 22 | 11.2 | 17.3 | 90 | 1199 | OD + TF + iv. glucose | No RS |
| Agostino et al., 2013 [ | Retrospective cohort study: | 165 | 14.9 | a: 16.6 | - | a: 33.8 | a: 1617 | a: 31 patients | No RS |
| Garber et al., 2013 [ | Prospective cohort: | 56 | 16.2 | a: 16.6 | - | 14.9 | a: 1700 | OD + ONS | No RS |
| Golden et al., 2013 [ | Retrospective | a: 88 | 16.1 | a: 15.9 | a: 17.2 | a: 16.6 | a: 1163 | OD + ONS + TF (occasionally) | No RS |
| Leclerc et al., 2013 [ | Retrospective | 29 | 14.7 | 16.4 | - | 35.8 | 1500 | OD + ONS | Hypophosphataemia (3.5%) |
| Hofer et al., 2014 [ | Retrospective | 65 | 27.9 | 13.7 | 15 | 49.5 | 10 kcal/kg | OD (mostly) | Mild RS (10.5%) |
| Brown et al., 2015 [ | Retrospective case-control | 123 | 28 | 13 | 13.9 | 13 | 1200 | OD | Hypophosphataemia (33%) |
| O’Connor et al., 2016 [ | RCT | a: 18 | 13.8 | a: 32.4 | a: 34.1 | 10 | a: 38 kcal/kg/d | OD + TF | a: Hypophosphataemia (28%) |
| Marugán et al., 2016 [ | Retrospective | 50 | 14.5 | 15.45 | 17.58 | 44.54 | 1000 | OD | No symptoms of RS |
| Kameoka et al., 2016 [ | Retrospective | 99 | 30.9 | <17.5 | - | 82.7 | Low calorie diet | OD | Hypophosphataemia (21.2%) |
| Smith et al., 2016 [ | Retrospective | 129 | 15.8 | 15.8 | 17.1 | 14.9 | 1585 | OD + ONS | No RS |
| Davies et al., 2017 [ | Retrospective | 65 | 24 | 12.8 | 14.4 | 60 | 20-30 | OD, ONS (infrequently) | Mild hypophosphataemia (<0.8 mmol/L) (6.5%) |
| Peebles et al., 2017 [ | Retrospective | 215 | 15.3 | 17.1 | 18.2 | 11 | 1466 | OD, TF (10%) | No RF. |
TF: Tube Feeding, OR: Oral Diet, ONS: Oral Nutritional Supplements, RS: Refeeding Syndrome, PN: Parenteral Nutrition, TPN: Total Parenteral Nutrition, RCT: Randomised Controlled Trial.
Identification of patients with high risk of refeeding syndrome.
| Patients with 1 or more of the following: |
BMI < 16 kg/m2 Unintentional weight loss of >15% in the previous 3–6 months. Minimum or no intake for >10 days. Low levels of K, P, or Mg before refeeding. |
| Or, patients with 2 or more of the following: |
BMI < 18.5 kg/m2 Unintentional weight loss of >10% in the previous 3–6 months Minimum or no intake for >5 days. History of alcohol abuse, drugs, insulin treatment, chemotherapy, antacids, or diuretics. |